As the official annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), EuroPCR is a patient-oriented Course built by and for the community covering the latest innovations and advances in cardiovascular interventions. Interventional cardiologists, cardiac surgeons, imaging specialists, radiologists, nurses, allied professionals and other practitioners will be joined by researchers, innovators and industry representatives to address interventions for coronary and peripheral vessels, for structural heart disease including valves, for hypertension, heart failure and stroke. And presentations of the latest devices and sessions on innovation in cardiovascular medicine - such as artificial intelligence and the cathlab of the future - will generate much interest. Over 700 participants will see their scientific abstracts, clinical cases, images, innovations and late-breaking trials showcased.

During EuroPCR, caIMR of RainMed is highly recognized and eagerly anticipated by top experts and scholars at home and abroad. Chief of cardiology department of Zhongshan Hospital, Fudan University and academician of Chinese Academy of Sciences Junbo Ge announced the excellent results of the clinical trial of Flash III supported by RainMed Medical.

It is a prospective, multicenter, blinded design registered clinical experiment to evaluate the efficacy and safety of caIMR. Based on a large number of data comparisons, caIMR has higher accuracy, sensitivity, and specificity than wire-based IMR. caIFR has also been recognized by clinical experts for its advantages of non-invasiveness, convenience, and no hyperemic agents.

In the Flash III clinical trial, 116 subjects accepted both caIMR test and guide wire-derived IMR test. Using caIMR≥25, IMR≥25 as the cut-off value to determine coronary microcirculation dysfunction, result showed that the accuracy of online and offline measurement was as high as 93.81% and 94.69% respectively. RainMed caIMR has such a high consistency with guide wire-derived IMR that it can accurately assess microcirculation dysfunction in patients with stable angina, unstable angina and non-obstructive coronary heart disease (INOCA) as well as replace guidewire-derived IMR for functional diagnosis of patients with ischemic heart disease.

Compared with cardiac MRI technology, caIMR has better clinical applicability. It can accurately measure microvascular resistance in real time and evaluate microvascular dysfunction after surgery. The clinical application of RainMed caIMR will also greatly improve the diagnosis and treatment of coronary heart disease caused by microcirculation. The simple way of functional vascular measurement will provide better prognostic assessment for STEMI patients, facilitate the development of microvascular function diagnosis and treatment, and pave the way for later clinical trials and large-scale applications.

caIMR is also able to work together with another revolutionary robust functional coronary angiography tool for the assessment of epicardial stenoses, caFFR, to provide a complete functional evaluation from the epicardial coronary artery to intramycardial microcirculation vessels. In this conference, Tommaso Gori, Professor at the University Medical Center of Mainz, Germany, and Javier Escaned, Head of the Interventional Cardiology Section at Hospital Clinico San Carlos (Madrid, Spain) also gave a special speech, highly praising the advantages, clinical value and scientific research achievements of caFFR.

Recently, caIMR has been successfully approved to enter the green channel of innovative medical devices, bringing sufficient confidence to accelerate the large-scale clinical application of the product. As a green channel for medical device approval, the special approval channel for innovative medical devices has a high approval threshold and a very low approval rate. Since the implementation of the approval process in 2014, only 170 products have been approved in China and the approval rate is only 20%. Among them, the caIMR and caFFR of RainMed and their supporting supplies have been successfully approved to enter the green channel of innovative medical devices.

In the future, RainMed Medical will integrate and form digital function diagnosis module covering caFFR and caIMR, build and launch panvascular automated diagnosis and treatment of the robot platform products, and extend to coronary artery, cerebrovascular, pulmonary artery, renal artery and other peripheral vascular. RainMed will uphold the principle of "Targeted medical services for the people’s health" and aims to reshape diagnosis and treatment in the industry and bring innovative treatment solutions for the majority of doctors and patients.